The NHS is expanding its respiratory syncytial virus (RSV) vaccination programme this September to include adults aged 65–74 with chronic respiratory conditions or suppressed immune systems. This move follows advice from the Joint Committee on Vaccination and Immunisation (JCVI) to protect those at a higher risk of severe outcomes from RSV infection, including hospitalisation, particularly during winter when cases peak.
Who is eligible for the expanded RSV vaccine?
Starting 1st September, the NHS will offer the vaccine to adults aged 65–74 who suffer from conditions such as chronic asthma, bronchitis, or cystic fibrosis. The eligibility also extends to individuals with weakened immune systems resulting from blood cancers, diabetes, or medical treatments like chemotherapy. According to the JCVI, these groups face a higher risk of severe outcomes from RSV, which is a common virus that infects the lungs.
How does the RSV vaccine protect patients?
The vaccine functions by introducing a small amount of RSV protein into the body, which stimulates the immune system to produce targeted antibodies. Dr. Conall Watson, a Consultant Epidemiologist at the UK Health Security Agency, states that this mechanism provides “excellent protection” against severe lung infection. By priming the immune system, the body can act much quicker to remove the threat, potentially preventing the need for hospital care.
Comparing current and previous vaccine roll-outs
The latest expansion builds on a series of vaccination efforts. Data published by NHS England shows that over 519,571 people aged 80 and over received the jab in the last three months alone. The programme already covers millions of people aged 75 and over, residents in care homes, and pregnant women. Since 2024, the programme has helped protect 300,000 mothers and babies in its first year alone, according to NHS figures.
Why is this expansion necessary for the NHS?
The primary goal of the expanded eligibility is to reduce the burden on the healthcare system during the winter months. Public Health Minister Sharon Hodgson stated that the programme will “prevent hundreds of avoidable hospital admissions” and decrease pressure on the NHS during the winter months. Caroline Temmink, Director of Vaccination at NHS England, emphasized that because RSV can cause serious illness, providing this protection is a critical step in keeping patients out of hospital.
Frequently Asked Questions
- Where can I get the RSV vaccine? Eligible patients can receive the jab at their local GP practice or, in some parts of the country, at their local high street pharmacy.
- Is the vaccine safe for those with underlying conditions? The JCVI identified these specific groups as having a higher risk of severe outcomes, and the vaccine is designed to provide protection for those with chronic lung conditions or weakened immune systems.
- Why is the NHS targeting the 65–74 age group? New evidence makes it clear that these groups of patients are at the highest risk of needing hospital admission due to RSV.
Are you eligible for the new round of vaccinations? Check with your local GP surgery today to ensure you are prepared for the winter season. For more updates on public health initiatives, subscribe to our newsletter or explore our latest health reports.
